Centene stock holds after 2026 EPS outlook is reaffirmed

Published on 09/20/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Centene stock kept its 2026 adjusted EPS outlook above USD 4.80 on September 20, 2026. Medicaid membership is now expected to fall 9% by year-end.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Centene stock (ISIN US15135B1017) held a 2026 adjusted EPS outlook above USD 4.80 on September 20, 2026, while the company now expects Medicaid membership to fall 9% by year-end. The update came from MarketBeat, which said Centene also kept its 93.5% health benefits ratio target for 2026.

Guidance stays firm

According to MarketBeat, Chief Executive Officer Sarah London said third-quarter performance through the first two months remained in line with expectations, and the company still sees a 4.5% to 5% margin in its marketplace business for 2026. The same report said Centene is aiming for break-even or better results in Medicare Advantage in 2027.

Centene also said Medicaid rates remain consistent with a roughly 5% full-year composite rate outlook, and Part D margins should stay above 3% in 2026. Those figures matter more than the stock's short-term reaction because they define how much pressure the business can absorb while membership trends soften.

Membership pressure rises

The most concrete counterweight is the membership outlook: Centene now expects Medicaid enrollment to decline 9% by year-end, compared with an earlier 6% to 8% forecast. MarketBeat said the company linked that shift to tighter eligibility checks ahead of work requirements.

The same update adds a useful investor signal: Centene is prioritizing profitability over growth, with a 2027 Medicare Advantage break-even target and a 2026 health benefits ratio target of 93.5%. For shareholders, the path is now clearer on margins than on volume.

Price and market level

Market data for Centene stock was not available in the search results of this call, so the fresh reference point is the guidance update on September 20, 2026. The article's core numbers are the 2026 EPS outlook above USD 4.80, the 93.5% health benefits ratio target, and the 9% Medicaid membership decline.